{% set version = "1.4.0" %}
{% set name = "DepInfeR" %}
{% set bioc = "3.17" %}

package:
  name: 'bioconductor-{{ name|lower }}'
  version: '{{ version }}'
source:
  url:
    - 'https://bioconductor.org/packages/{{ bioc }}/bioc/src/contrib/{{ name }}_{{ version }}.tar.gz'
    - 'https://bioconductor.org/packages/{{ bioc }}/bioc/src/contrib/Archive/{{ name }}/{{ name }}_{{ version }}.tar.gz'
    - 'https://bioarchive.galaxyproject.org/{{ name }}_{{ version }}.tar.gz'
    - 'https://depot.galaxyproject.org/software/bioconductor-{{ name|lower }}/bioconductor-{{ name|lower }}_{{ version }}_src_all.tar.gz'
  md5: dcf243eeb7152508a9beb10faa48f249
build:
  number: 0
  rpaths:
    - lib/R/lib/
    - lib/
  noarch: generic
# Suggests: testthat (>= 3.0.0), knitr, rmarkdown, dplyr, tidyr, tibble, ggplot2, missForest, pheatmap, RColorBrewer, ggrepel, BiocStyle, ggbeeswarm
requirements:
  host:
    - 'bioconductor-biocparallel >=1.34.0,<1.35.0'
    - r-base
    - r-glmnet
    - r-matrixstats
  run:
    - 'bioconductor-biocparallel >=1.34.0,<1.35.0'
    - r-base
    - r-glmnet
    - r-matrixstats
test:
  commands:
    - '$R -e "library(''{{ name }}'')"'
about:
  home: 'https://bioconductor.org/packages/{{ bioc }}/bioc/html/{{ name }}.html'
  license: GPL-3
  summary: 'Inferring tumor-specific cancer dependencies through integrating ex-vivo drug response assays and drug-protein profiling'
  description: 'DepInfeR integrates two experimentally accessible input data matrices: the drug sensitivity profiles of cancer cell lines or primary tumors ex-vivo (X), and the drug affinities of a set of proteins (Y), to infer a matrix of molecular protein dependencies of the cancers (ß). DepInfeR deconvolutes the protein inhibition effect on the viability phenotype by using regularized multivariate linear regression. It assigns a “dependence coefficient” to each protein and each sample, and therefore could be used to gain a causal and accurate understanding of functional consequences of genomic aberrations in a heterogeneous disease, as well as to guide the choice of pharmacological intervention for a specific cancer type, sub-type, or an individual patient. For more information, please read out preprint on bioRxiv: https://doi.org/10.1101/2022.01.11.475864.'
  license_file: '{{ environ["PREFIX"] }}/lib/R/share/licenses/GPL-3'

